In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Vir Biotechnology Inc (NASDAQ: VIR) was $5.76 for the day, down -2.87% from the previous closing price of $5.93. In other words, the price has decreased by -$2.87 from its previous closing price. On the day, 5.13 million shares were traded. VIR stock price reached its highest trading level at $6.0599 during the session, while it also had its lowest trading level at $5.73.
Ratios:
Our analysis of VIR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.25 and its Current Ratio is at 7.25. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In the most recent recommendation for this company, Evercore ISI on September 03, 2025, initiated with a Outperform rating and assigned the stock a target price of $12.
On August 27, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $14. JP Morgan Downgraded its Overweight to Neutral on January 29, 2024, whereas the target price for the stock was revised from $23 to $9.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 01 ’25 when SVF Endurance (Cayman) Ltd sold 191,854 shares for $5.98 per share. The transaction valued at 1,147,786 led to the insider holds 13,728,924 shares of the business.
SATO VICKI L sold 22,000 shares of VIR for $132,070 on Dec 01 ’25. The Director now owns 1,188,391 shares after completing the transaction at $6.00 per share. On Nov 26 ’25, another insider, SVF Endurance (Cayman) Ltd, who serves as the 10% Owner of the company, sold 127,938 shares for $6.39 each. As a result, the insider received 817,652 and left with 13,982,271 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 801360192 and an Enterprise Value of 395022176. For the stock, the TTM Price-to-Sale (P/S) ratio is 47.53 while its Price-to-Book (P/B) ratio in mrq is 1.01. Its current Enterprise Value per Revenue stands at 23.43 whereas that against EBITDA is -0.772.
Stock Price History:
The Beta on a monthly basis for VIR is 1.40, which has changed by -0.21525884 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $4.16. The 50-Day Moving Average of the stock is -3.58%, while the 200-Day Moving Average is calculated to be 3.02%.
Shares Statistics:
VIR traded an average of 1.59M shares per day over the past three months and 2089280 shares per day over the past ten days. A total of 139.02M shares are outstanding, with a floating share count of 94.03M. Insiders hold about 32.42% of the company’s shares, while institutions hold 54.22% stake in the company. Shares short for VIR as of 1764288000 were 11110359 with a Short Ratio of 6.98, compared to 1761868800 on 9581029. Therefore, it implies a Short% of Shares Outstanding of 11110359 and a Short% of Float of 12.86.
Earnings Estimates
. The current rating of Vir Biotechnology Inc (VIR) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.61, with high estimates of -$0.45 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$3.02 and -$3.62 for the fiscal current year, implying an average EPS of -$3.36. EPS for the following year is -$2.91, with 9.0 analysts recommending between -$2.3 and -$3.63.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $66M to a low estimate of $240k. As of. The current estimate, Vir Biotechnology Inc’s year-ago sales were $12.37MFor the next quarter, 7 analysts are estimating revenue of $2.37M. There is a high estimate of $4.5M for the next quarter, whereas the lowest estimate is $310k.
A total of 9 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $70.5M, while the lowest revenue estimate was $4.73M, resulting in an average revenue estimate of $20.8M. In the same quarter a year ago, actual revenue was $74.2MBased on 9 analysts’ estimates, the company’s revenue will be $9.68M in the next fiscal year. The high estimate is $18.1M and the low estimate is $1.22M.
